Attorney Docket No.: 5974.200-US

**PATENT** 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: Poul Bach

Serial No.: 09/675,952

Group Art Unit: To be assigned

Filed: September 29, 2000

Examiner: To be assigned

For: Enzyme Granulate

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box DD Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Information Disclosure Statement
- 2. PTO-1449 Form
- 3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD Commissioner for Patents Washington, DC 20231

on November 2, 2000.

Kelley O'Patry

(name of person mailing paper)

(signature of person mailing paper)

Attorney Docket No.: 5974.200-US

**PATENT** 

#

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Poul Bach

Application No.: 09/675,952

Group Art Unit: To be assigned

Filed: September 29, 2000

Examiner: To be assigned

For: Enzyme Granulate

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

- 1. WO 97/39116
- 2. WO 90/09440
- 3. WO 90/09428
- 4. US 4,016,040
- 5. US 4,713,245

6. US 4,106,991

7. EP 0 170 360 B1

8. EP 0 304 332 B1

9. EP 304 331 B1

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: November 2, 2000

Elias J. Lambiris, Reg. No. 33,728 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123